Can single-cell genomics lead to a new wave of drug targets? Celsius Therapeutics thinks so

The start-up, based on the work of Broad Institute scientist Aviv Regev, has raised $65 million to develop therapies for cancer and autoimmune disease

via Chemical & Engineering News: Biological SCENE https://ift.tt/2wCQGM2